Precision medicine describes how genetic information is used to characterize a person’s disease, and provide doctors with more accurate diagnosis and treatment options; This in turn gives patients a higher rate of survival. Cancer is a disease of the genome, and as more is learned about cancer tumors, the more we can find that each tumor has its own set of genetic changes. Understanding the genetic changes in cancer cells is leading to more effective treatment strategies that are tailored to the genetic profile of each patients cancer.
OptiCancer analyzes every detail of molecular-genetic structure of an individual’s cancer tissue, and gathers all cancer-relevant genetic mutations into a mutational landscape. This mutational landscape is then compared to information from other cancer tissues, which has been gathered from renowned scientific journals, clinical studies and highly specialized computer databases. When there is a match between a patients mutational landscape and another in the database, a list of possible treatment options are indexed. The doctor is presented with a summative report with a list of suitable therapies which can aid in making an improved decision regarding the patients treatment.
“Cancer is a life-threatening disease whose diagnosis and treatment requires the utmost precision, rapid and correct diagnosis, individual therapies and how they should be adjusted over time are essential to successfully fighting cancer. “
– Dr. Friedrich von Bohlen, Chairman at Molecular Health
“Precision Medicine is an approach to discover and develop medicines, vaccines or routes of intervention (behavior, nutrition, etc.) that enable disease prevention and deliver superior therapeutic outcomes for patients, by integrating clinical, molecular (multi-omics including epigenetics), environmental and behavioral (Big Data) information to understand the biological basis of disease. This effort leads to better selection of disease targets and identification of patient populations that demonstrate improved clinical outcomes to novel preventive and therapeutic approaches. In order to achieve this goal novel standards to harvest raw data (SOPs), processes, as well as architectures/analytics and mobile ICT technologies are instrumental to enable implementation and delivery of Precision Medicine 24/7 anywhere anytime in the world. Data in general will become the crude oil and currency of the future, while safety, security, ownership, privacy and so on constitute ethical challenges that need to be discussed alongside technical solutions to foster novel business and improve health care. “
– Thomas Wilckens, CEO InnVentis Ltd., Precision Medicine leader.
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
– Charles Darwin
“Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals. You can match a blood transfusion to a blood type. That was an important discovery. What if matching a cancer cure to our genetic code was just as easy, just as standard? What if figuring out the right dose of medicine was as simple as taking our temperature? And that’s the promise of precision medicine — delivering the right treatments, at the right time, every time to the right person. And for a small but growing number of patients, that future is already here. “
– Barack Obama
“Through advances in research, technology and policies that empower patients, the PMI will enable a new era of medicine in which researchers, providers and patients work together to develop individualized care.” While oncology is an avant-garde field of Precision Medicine, the practice currently is not in use for most diseases. In summary, it bears an immense potential, but is still in its infancy.”
– Barack Obama
“Technological advances have paved the way for a precision treatment tailored to both patient and tumor. DNA is the key to targeted anti-cancer therapies. We want to use our knowledge to prevent people from going into treatments they won’t respond to”.
– RolandKanaar, professor in molecular radiation genetics, Erasmus MC.